menu
    • menu
    [{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.44,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.44,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Pharmacare Holdings \/ Sandoz"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"SINTETICA SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SINTETICA SA \/ Not Applicable"},{"orgOrder":0,"company":"Sustained Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sustained Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sustained Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sustained Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","graph1":null,"graph2":null,"graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eugia Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lidocaine HCl

    Menu

    Lidocaine HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen Pharmacare Holdings

                            South Africa
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : $440.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third l...

                            Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.

                            Brand Name : Lidocaine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : $330.0 million

                            January 31, 2020

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : $440.0 million

                            Deal Type : Acquisition

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eugia Pharma

                            India arrow
                            Compamed
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Steriles Receives FDA Approval for New Injectables Facility

                            Details : Lidocaine is a local anesthetic that's used to numb areas of the body before medical procedures, treat pain, and treat certain heart conditions.

                            Brand Name : Lidocaine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2024

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sustained Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Sustained Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform

                            Details : ST-01 is a controlled release formulation of lidocaine, a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels preventing pain signals at the nerve endings. It is being developed for acute p...

                            Brand Name : ST-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2023

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SINTETICA SA

                            Switzerland arrow
                            Compamed
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

                            Details : Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.

                            Brand Name : Lidocaine Hydrochloride-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2023

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%

                            Details : Amneal has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic n...

                            Brand Name : Lidocaine HCl- Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2020

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth